EUVIMEDEUVIMED entdecken
Crossref

Lanthanum carbonate does not reduce urinary oxalate excretion in hyperoxaluric kidney stone formers

Els Van de Perre iD, Christian Tielemans, Dieter De Clerck, Agnieszka Pozdzik, Philippe Durieux, Sophie Boesmans, Frederik Tielens, Simon van Hooland, Patrick D'Haese, Ronny Blust, Frédéric Cotton, Karl Martin Wissing iD

Nephrology Dialysis Transplantation · 07.05.2026

DOI: 10.1093/ndt/gfag103 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 07.05.2026. Verfasst von Els Van de Perre und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Arterial Hypertension, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Brussels, Belgium. Die Arbeit nennt 48 Literaturangaben. Gefördert von: Department of Nephrology of the Universitair Ziekenhuis Brussel.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and hypothesis Hyperoxaluria is an important risk factor for kidney stone formation. Currently available treatment options for idiopathic hyperoxaluria have limited efficacy and are difficult to maintain in the long-term. Preclinical data suggested that lanthanum carbonate (LaCa) might efficiently bind oxalate. In this multicenter, open-label, dose–response study, we assessed the efficacy and safety of LaCa in the reduction of urinary oxalate excretion in stone formers with idiopathic hyperoxaluria.

Methods

Stone formers with urinary oxalate excretion >45 mg/24 h were treated with LaCa at a dose of 750 mg daily during a first 14-day treatment period, followed by a second 14-day treatment period with 1500 mg LaCa daily. The study was powered for the primary efficacy endpoint of detecting a ≥20% urinary oxalate excretion reduction after the first treatment period (AFTP). Secondary endpoints were the incremental reduction of urinary oxalate excretion with LaCa dose increase to 1500 mg during the second treatment period and the effect on serum phosphate and urinary phosphate excretion.

Results

Forty-four patients started the study, 42 completed the 2 months follow-up. LaCa treatment with both the 750 and 1500 mg dose had no effect on urinary oxalate excretion [52.0 mg/24 h at baseline (BL), 49.1 mg/24 h AFTP (P = .25), and 52.6 mg/24 h after second treatment period (ASTP; P = .01 compared to AFTP, P = .86 compared to BL)]. Urinary phosphate/creatinine ratio and fractional excretion (FE) of phosphate decreased significantly after treatment with 1500 mg LaCa (17.1 mmol/g at BL, 15.2 mmol/g ASTP, P = .003 for urinary phosphate/creatinine ratio and 16.6% at BL, 14.7% ASTP, P = .002 for FE phosphate), while LaCa had no effect on serum phosphate (0.97 mmol/l at BL, 0.95 mmol/l ASTP, P = .29).

Conclusion

Short-term treatment with LaCa at doses up to 1500 mg did not reduce urinary oxalate excretion in stone formers with idiopathic hyperoxaluria. Urinary phosphate excretion decreased without effect on serum phosphate. Clinical trial registration number (ClinicalTrials.gov) NCT03346369

Schlagwörter

Stichwörter der Autor:innen

hyperoxaluriakidney stoneslanthanum carbonatenephrolithiasisoxalate

Autor:innen und Institutionen

  • Department of Nephrology and Arterial Hypertension, Universitair Ziekenhuis Brussel (UZ Brussel), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
  • Kidney Diseases, Dialysis & Transplantation Research Unit (NIER), Vitality Research Group, Vrije Universiteit Brussel (VUB), Brussels, Belgium.
  • Department of Nephrology and Dialysis, Kidney Stone Clinic, University Hospital Brugmann, Brussels, Belgium.
  • Faculty of Medicine, Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Department of Nephrology, Centre Hospitalier Wallonie Picarde, site IMC-Tournai, Tournai, Belgium.
  • General Chemistry (ALGC) - Materials Modelling Group, Vrije Universiteit Brussel (VUB), Brussels, Belgium.

ORCID-Profile: Els Van de Perre, Karl Martin Wissing

Förderung

  • Department of Nephrology of the Universitair Ziekenhuis Brussel

Zitieren

APA

Van de Perre, E., Tielemans, C., De Clerck, D., Pozdzik, A., Durieux, P., Boesmans, S., Tielens, F., van Hooland, S., D'Haese, P., Blust, R., Cotton, F., & Wissing, K. M. (2026). Lanthanum carbonate does not reduce urinary oxalate excretion in hyperoxaluric kidney stone formers. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfag103

Vancouver

Van de Perre E, Tielemans C, De Clerck D, Pozdzik A, Durieux P, Boesmans S, et al. Lanthanum carbonate does not reduce urinary oxalate excretion in hyperoxaluric kidney stone formers. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfag103

BibTeX
@article{VandePerre2026,
  author = {Van de Perre, Els and Tielemans, Christian and De Clerck, Dieter and Pozdzik, Agnieszka and Durieux, Philippe and Boesmans, Sophie and Tielens, Frederik and van Hooland, Simon and D'Haese, Patrick and Blust, Ronny and Cotton, Frédéric and Wissing, Karl Martin},
  title = {Lanthanum carbonate does not reduce urinary oxalate excretion in hyperoxaluric kidney stone formers},
  journal = {Nephrology Dialysis Transplantation},
  year = {2026},
  doi = {10.1093/ndt/gfag103}
}
Kostenlos starten →